Parkinson’s Disease: Debunking an old theory
A group of structures deep inside the brain are thought to be responsible for the progression of Parkinson’s disease. These structures, known as the basal ganglia, play an important role in coordinating movement via two opposing motor pathways: the ‘indirect pathway’ which suppresses movement, and the ‘direct pathway’ which promotes movement. It has been reported that overactivation of the indirect pathway and underactivation of the direct pathway lead to the motor impairments associated with Parkinson’s disease (Albin et al., 1989; Bergman et al., 1990; Gerfen et al., 1990).
Previous studies investigating the cellular mechanisms that cause these abnormalities have largely focused on spiny projection neurons (SPNs for short), a group of cells found in a basal ganglia structure known as the striatum. These cells express one of two types of dopamine receptors called D1 and D2. SPNs expressing D1 are frequently referred to as the origin of the direct pathway, whereas SPNs expressing D2 are referred to as the origin of the indirect pathway. These pathways then pass this signal between multiple structures of the basal ganglia until they reach a group of cells known as the output nuclei.
The striatum receives most of its dopamine from an area in the brain that degenerates in Parkinson’s disease. This loss in dopamine is thought to reduce the activity of D1-SPNs and increase the activity of D2-SPNs, causing neurons in the striatum to fire at different rates: this is predicted to drive the excessive activity of the indirect pathway and reduced activity of the direct pathway, which leads to pathological activity throughout the basal ganglia (Gerfen and Surmeier, 2011; Figure 1A). This hypothesis is known as the ‘rate model’ and has had a huge influence on the field of Parkinson’s disease. Yet, there has been limited in vivo evidence showing the firing rates of SPNs changing, particularly from human patients.
Now, in eLife, Marc Deffains (University of Bordeaux) and colleagues – including Dan Valsky (Hebrew University of Jerusalem) as first author – report experiments investigating the firing rates of SPNs in patients with Parkinson’s disease (Valsky et al., 2020). The team were able to gather data from human patients who were undergoing a surgical procedure that implants electrodes into deep regions of the brain. Valsky et al. found that the firing rates of SPNs in patients with Parkinson’s disease were no different than expected values found in healthy non-human primates. Further computational analysis, clustering the different firing rates detected, was unable to identify two distinct populations of neurons that could represent overactive D2-SPNs and underactive D1-SPNs.
These results were in contrast to the only other human study which supports the predictions made by the rate model (Singh et al., 2016). However, both studies used a different method to isolate and analyze the activity of neurons. Valsky et al. applied strict criteria to ensure that the firing rates recorded only came from well-isolated, stationary single units. This minimizes the chance of other factors, such as noise from movement or signals from damaged cells, interfering with the firing rates being measured. Valsky et al. showed that when these criteria were not in place, they were able to replicate the changes in activity reported in the previous study, but argued that this is a spurious conclusion.
The fact that Valsky et al. were not able to find evidence for the rate model within the striatum was not entirely unexpected, as the exceptions and limitations of this model have become increasingly documented (Obeso and Lanciego, 2011). Other models have proposed that the abnormalities observed in the basal ganglia arise from neurons changing their patterns of activity to fire more irregularly or with increased oscillations (Nelson and Kreitzer, 2014). But when Valsky et al. searched their data for these other patterns of activity, they could not detect any of these features in the striatal neurons of patients with Parkinson’s disease (Figure 1B).
These findings raise a lot of questions about the role the striatum plays in the motor impairments associated with Parkinson’s disease. However, two critical variables that were not addressed in this study are synchrony (non-oscillatory), and total neuron recruitment within the striatum. When multiple SPNs fire simultaneously, this relays a more powerful signal to downstream areas of the brain than if SPNs are activated independently. Therefore, if dopamine depletion enabled more D2-SPNs to activate simultaneously, or in greater numbers, this could lead to increase indirect pathway output from the striatum. However, the techniques used to record neuronal activity in this study means it is not possible to determine whether this change occurred.
These findings highlight the need for a critical reassessment of long-standing assumptions about the cellular mechanisms involved in the onset of Parkinson’s disease. Even if this study does not completely rule out the striatum as a source of basal ganglia abnormalities in this condition, it narrows down the types of changes that might be responsible. It also emphasizes the roles of brain structures that are traditionally considered to be ‘downstream’ of the striatum in generating the neuronal defects associated with Parkinson’s disease (Figure 1B). Furthermore, this work provides a valuable, rigorously curated data set which will be beneficial to the field.
References
-
The functional anatomy of basal ganglia disordersTrends in Neurosciences 12:366–375.https://doi.org/10.1016/0166-2236(89)90074-X
-
Modulation of striatal projection systems by dopamineAnnual Review of Neuroscience 34:441–466.https://doi.org/10.1146/annurev-neuro-061010-113641
-
Reassessing models of basal ganglia function and dysfunctionAnnual Review of Neuroscience 37:117–135.https://doi.org/10.1146/annurev-neuro-071013-013916
-
Past, present, and future of the pathophysiological model of the basal gangliaFrontiers in Neuroanatomy 5:39.https://doi.org/10.3389/fnana.2011.00039
Article and author information
Author details
Publication history
Copyright
© 2020, Spix and Gittis
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,000
- views
-
- 176
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Evolutionary Biology
- Medicine
Male germ cells share a common origin across animal species, therefore they likely retain a conserved genetic program that defines their cellular identity. However, the unique evolutionary dynamics of male germ cells coupled with their widespread leaky transcription pose significant obstacles to the identification of the core spermatogenic program. Through network analysis of the spermatocyte transcriptome of vertebrate and invertebrate species, we describe the conserved evolutionary origin of metazoan male germ cells at the molecular level. We estimate the average functional requirement of a metazoan male germ cell to correspond to the expression of approximately 10,000 protein-coding genes, a third of which defines a genetic scaffold of deeply conserved genes that has been retained throughout evolution. Such scaffold contains a set of 79 functional associations between 104 gene expression regulators that represent a core component of the conserved genetic program of metazoan spermatogenesis. By genetically interfering with the acquisition and maintenance of male germ cell identity, we uncover 161 previously unknown spermatogenesis genes and three new potential genetic causes of human infertility. These findings emphasize the importance of evolutionary history on human reproductive disease and establish a cross-species analytical pipeline that can be repurposed to other cell types and pathologies.
-
- Medicine
Gremlin-1 has been implicated in liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) via inhibition of bone morphogenetic protein (BMP) signalling and has thereby been identified as a potential therapeutic target. Using rat in vivo and human in vitro and ex vivo model systems of MASH fibrosis, we show that neutralisation of Gremlin-1 activity with monoclonal therapeutic antibodies does not reduce liver inflammation or liver fibrosis. Still, Gremlin-1 was upregulated in human and rat MASH fibrosis, but expression was restricted to a small subpopulation of COL3A1/THY1+ myofibroblasts. Lentiviral overexpression of Gremlin-1 in LX-2 cells and primary hepatic stellate cells led to changes in BMP-related gene expression, which did not translate to increased fibrogenesis. Furthermore, we show that Gremlin-1 binds to heparin with high affinity, which prevents Gremlin-1 from entering systemic circulation, prohibiting Gremlin-1-mediated organ crosstalk. Overall, our findings suggest a redundant role for Gremlin-1 in the pathogenesis of liver fibrosis, which is unamenable to therapeutic targeting.